Forte Biosciences, Inc. financial data

Symbol
FBRX on Nasdaq
Industry
Pharmaceutical Preparations
Location
3060 Pegasus Park Drive, Building 6, Dallas, TX
State of incorporation
DE
Fiscal year end
December 31
Former names
Tocagen Inc (to 6/15/2020)
Latest financial report
10-K - Q4 2024 - Mar 28, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 452 % -37.1%
Return On Equity -132 % -40%
Return On Assets -103 % -26.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.58M shares -81.9%
Common Stock, Shares, Outstanding 6.39M shares +340%
Entity Public Float 18.3M USD -10.3%
Common Stock, Value, Issued 6K USD +500%
Weighted Average Number of Shares Outstanding, Basic 21M shares +42.6%
Weighted Average Number of Shares Outstanding, Diluted 21M shares +42.6%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 15.4M USD +45%
Operating Income (Loss) -36.6M USD -12.7%
Net Income (Loss) Attributable to Parent -35.5M USD -12.7%
Earnings Per Share, Basic -12.2 USD/shares +51.2%
Earnings Per Share, Diluted -12.2 USD/shares +51.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 22.2M USD -40.1%
Cash, Cash Equivalents, and Short-term Investments 58.4M USD
Assets, Current 61.3M USD +60.1%
Property, Plant and Equipment, Net 77K USD -29.4%
Other Assets, Noncurrent 138K USD -74.6%
Assets 61.6M USD +57.9%
Accounts Payable, Current 4.88M USD +243%
Accrued Liabilities, Current 4.2M USD +87.4%
Liabilities, Current 9.08M USD +148%
Accumulated Other Comprehensive Income (Loss), Net of Tax 11K USD +175%
Retained Earnings (Accumulated Deficit) -154M USD -29.9%
Stockholders' Equity Attributable to Parent 52.5M USD +48.6%
Liabilities and Equity 61.6M USD +57.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.67M USD -28.1%
Net Cash Provided by (Used in) Financing Activities -8K USD -233%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 6.39M shares +340%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.68M USD -28.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 22.2M USD -40.1%
Deferred Tax Assets, Valuation Allowance 24.5M USD +31.7%
Deferred Tax Assets, Gross 24.5M USD +31.7%
Depreciation 9K USD
Payments to Acquire Property, Plant, and Equipment 6K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -35.5M USD -12.7%
Property, Plant and Equipment, Gross 125K USD +5.93%
Deferred Tax Assets, Operating Loss Carryforwards 7.64M USD +17.2%
Unrecognized Tax Benefits 411K USD +63.7%
Share-based Payment Arrangement, Expense 3.1M USD -5.76%